Mechanisms in Chronic Myelogenous Leukemia –
Accreditation Information
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Imedex, LLC designates the following activities for
AMA PRA Category 1 Credits™,
to a maximum of:
Participants who are eligible to claim AMA PRA Category 1 Credits™ must complete
the self-assessment questions and module evaluation after reviewing the content of each Learning Module.
Hours Calculated:
A CME Review of each Learning Module was conducted to determine the credit designation for each activity. The estimated time to complete each and the credits assigned are as follows:
| | Estimated Completion Time | Credit Awarded | Release Date | Expiration Date |
|
Biology and Pathophysiology of Chronic Myelogenous Leukemia
|
120 minutes
|
2.00
|
11/30/08
|
11/30/09
|
|
Clinical Manifestations and Laboratory Studies
|
90 minutes
|
1.50
|
11/30/08
|
11/30/09
|
|
Current Treatment of Chronic Myelogenous Leukemia – Imatinib and Allogeneic SCT
|
60 minutes
|
1.00
|
11/30/08
|
11/30/09
|
|
Mechanisms of Resistance
|
150 minutes
|
2.50
|
11/30/08
|
11/30/09
|
|
Treatment of Imatinib Resistant Chronic Myelogenous Leukemia
|
90 minutes
|
1.50
|
11/30/08
|
11/30/09
|
|
Monitoring of Treatment of Chronic Myelogenous Leukemia
|
120 minutes
|
2.00
|
11/30/08
|
11/30/09
|
|
Chronic Myelogenous Leukemia Treatment Guidelines
|
60 minutes
|
1.00
|
11/30/08
|
11/30/09
|
|
Questions on Management and Treatment: Side Effects and Drug Interactions
|
90 minutes
|
1.50
|
11/30/08
|
11/30/09
|
| | |
13.00
| | |